Grant: Operating Grant

Genetic methods will be used to direct white blood cells against targets that are present on tumors. This strategy allows scientists to harness the robust tumor-fighting properties of white blood cells and direct them selectively against the tumor. Given the power of the white blood cells, there is some concern of that the white blood cells may also attack healthy tissues. We have developed a novel method that produces a white blood cell which selectively attacks tumor tissue while leaving healthy tissue unaffected. We propose to use the funds provided by this grant to confirm our new technology with the intention of moving it into clinical trial. We also propose to investigate the outcome of combining our white blood cell therapy with a novel class of specially-modified viruses which selectively infect and kill tumors. The combined treatment is expected to provide a powerful immune stimulation that will provide long-term control of future tumor outgrowth. Our research program employs cutting-edge technologies that are unique in Canada and offers an excellent opportunity for training young scientists.